SCHEMBL1562841

SCHEMBL1562841

CCC(=O)On1nnc2ccccc2c1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 1/20 0.60
ALDH1A1 P00352 6/20 0.52
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 2/20 0.48
POLB P06746 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
HPGD P15428 4/20 0.47
KDM4E B2RXH2 2/20 0.47
TSHR P16473 2/20 0.47
HSD17B10 Q99714 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GPR139 Q6DWJ6 1/20 0.46
MAPK1 P28482 2/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1561845 0.85 HPSE (0.53) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL3072842 0.85 HPSE (0.56) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL6234424 0.84 HPSE (0.52) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL19649562 0.84 HPSE (0.53) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL10098857 0.82 ALDH1A1 (0.51) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL18493192 0.82 HPSE (0.50) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL5651138 0.81 HPSE (0.50) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL25734944 0.81 HPSE (0.50) HPSEALDH1A1KMT2AMEN1LMNA
SCHEMBL1562499 0.81 ALDH1A1 (0.54) HPSEALDH1A1LMNANPSR1SMN1; SMN2
SCHEMBL8779471 0.80 HDAC3 (0.58) ALDH1A1KMT2APOLBNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200282071-A1 CONJUGATES OF PROTEIN DRUGS AND P/A PEPTIDES XL-PROTEIN GMBH (DE) 2020-09-10 US disclosed
US-8575391-B2 5-substituted-2-phenylamino benzamides as MEK inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-11-05 US disclosed
EP-1780197-B9 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2011-04-06 EP disclosed
EP-1780197-B1 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-10-20 EP disclosed
US-20100197676-A1 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-08-05 US disclosed
US-7745663-B2 5-Substituted-2-phenylamino benzamides as MEK inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-06-29 US disclosed
US-20090233915-A1 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-09-17 US disclosed
EP-1780197-A1 5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200282071-A1 CONJUGATES OF PROTEIN DRUGS AND P/A PEPTIDES PTMS, ANPEP, FCGRT HPSE 1797/4885ALDH1A1 3465/4885KMT2A 3022/4885
US-20100197676-A1 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors BRAF, RAF1, NRAS HPSE 4173/4885ALDH1A1 680/4885KMT2A 525/4885
US-20090233915-A1 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors BRAF, RAF1, NRAS HPSE 4173/4885ALDH1A1 680/4885KMT2A 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.